Science Advances · 20 Nov 2026
Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma
Amy Y. Huangh-index 5, Kelly P. Burke, Marc C. Glettig, Ryan Porter, Peter Fatouros, Jonathan M. Li, Lynn Meiger, Valeria Rosado, Shuyun Xu, Jiekun Yang, Emily Robitschek, Natalie Vokes, Cora Ricker, Giuseppe Tarantino, Jiajia Chen, Tyler J. Aprati, Yiwen He, Cassia Wang, Doris Fu, Li-Lun Ho, Kyriakitsa Galani, Gordon J. Freemanh-index 171, Elizabeth I. Buchbinder, F. Stephen Hodi, Christine G. Lian, Manolis Kellis, Genevieve M. Boland, Arlene H. Sharpe, David Liuh-index 37
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
While immune-checkpoint blockade (ICB) has revolutionized treatment of metastatic melanoma, the identification of robust biomarkers to predict the relative efficacy of single versus combination ICB has been challenging. We performed a meta-analysis of eight cohorts of patients treated with anti–PD-1 ( n = 290), anti–CTLA-4 ( n = 175), and combination anti–PD-1/anti–CTLA-4 ( n = 51) with pretreatment tumor sequencing and clinical annotations. Surprisingly, the increased response rate to combination anti–PD-1/anti–CTLA-4 compared to anti–PD-1 monotherapy was observed only in highly immune infiltrated tumors, and not in immune-low tumors. Stratifying tumors by high or low frequency of immune cells also distinguished context-dependent programs of primary resistance to single and combination ICB. Notably, hypoxia-related pathways were enriched in nonresponders to anti–PD-1 ICB in immune-high, but not immune-low, tumors. Using an independent cohort of patients with scRNA-seq data, we observed that correlates of hypoxia were associated with increased stromal tumor receptor-ligand interactions. As proof of concept, selective inhibition of HIF-2α, a component of the hypoxia pathway and highly expressed in endothelial cells and fibroblasts, in combination with anti–PD-1, controlled tumor growth in mouse models of highly immune-infiltrated tumors but not poorly immune-infiltrated tumors. Our work demonstrates how stratification by tumor immune characteristics and clinical features can lead to the rational discovery of novel therapeutic targets.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Gordon J. Freeman has the highest h-index among the authors (171).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (84)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 64 more references
A free account opens the rest of the citing papers and references on every paper’s page.